Heron Therapeuti (HRTX) - Net Assets
Based on the latest financial reports, Heron Therapeuti (HRTX) has net assets worth $9.14 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($246.22 Million) and total liabilities ($237.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Heron Therapeuti (HRTX) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.14 Million |
| % of Total Assets | 3.71% |
| Annual Growth Rate | -0.48% |
| 5-Year Change | -81.52% |
| 10-Year Change | N/A |
| Growth Volatility | 223.27 |
Heron Therapeuti - Net Assets Trend (1987–2025)
This chart illustrates how Heron Therapeuti's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Heron Therapeuti market cap and net worth.
Annual Net Assets for Heron Therapeuti (1987–2025)
The table below shows the annual net assets of Heron Therapeuti from 1987 to 2025. Also explore Heron Therapeuti equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $14.33 Million | +142.59% |
| 2024-12-31 | $-33.65 Million | +0.95% |
| 2023-12-31 | $-33.97 Million | -350.32% |
| 2022-12-31 | $13.57 Million | -82.50% |
| 2021-12-31 | $77.57 Million | -67.20% |
| 2020-12-31 | $236.49 Million | -41.44% |
| 2019-12-31 | $403.83 Million | +9.10% |
| 2018-12-31 | $370.16 Million | +182.27% |
| 2017-12-31 | $131.14 Million | +717.08% |
| 2016-12-31 | $-21.25 Million | -117.99% |
| 2015-12-31 | $118.11 Million | +87.29% |
| 2014-12-31 | $63.06 Million | -8.53% |
| 2013-12-31 | $68.94 Million | +33.05% |
| 2012-12-31 | $51.82 Million | +228.96% |
| 2011-12-31 | $15.75 Million | +1096.96% |
| 2010-12-31 | $1.32 Million | -80.64% |
| 2009-12-31 | $6.80 Million | -10.56% |
| 2008-12-31 | $7.60 Million | -74.22% |
| 2007-12-31 | $29.47 Million | +144.41% |
| 2006-12-31 | $12.06 Million | +94.41% |
| 2005-12-31 | $6.20 Million | -56.17% |
| 2004-12-31 | $14.15 Million | +25.67% |
| 2003-12-31 | $11.26 Million | -27.14% |
| 2002-12-31 | $15.46 Million | -19.37% |
| 2001-12-31 | $19.17 Million | -9.39% |
| 2000-12-31 | $21.16 Million | +76.33% |
| 1999-12-31 | $12.00 Million | -17.24% |
| 1998-12-31 | $14.50 Million | +42.16% |
| 1997-12-31 | $10.20 Million | +104.00% |
| 1996-12-31 | $5.00 Million | -3.85% |
| 1995-12-31 | $5.20 Million | -55.93% |
| 1994-12-31 | $11.80 Million | +12.38% |
| 1993-12-31 | $10.50 Million | -48.02% |
| 1992-12-31 | $20.20 Million | +531.25% |
| 1991-12-31 | $3.20 Million | -49.21% |
| 1990-12-31 | $6.30 Million | -33.68% |
| 1989-12-31 | $9.50 Million | -28.57% |
| 1988-12-31 | $13.30 Million | -22.67% |
| 1987-12-31 | $17.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Heron Therapeuti's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 193008900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.88 Million | 13.14% |
| Other Comprehensive Income | $4.00K | 0.03% |
| Other Components | $1.95 Billion | 13620.56% |
| Total Equity | $14.33 Million | 100.00% |
Heron Therapeuti Competitors by Market Cap
The table below lists competitors of Heron Therapeuti ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Suprema ID Inc
KQ:317770
|
$58.63 Million |
|
Mesa Air Group Inc
NASDAQ:MESA
|
$58.63 Million |
|
Mastermyne Group Ltd
AU:MYE
|
$58.64 Million |
|
Gemfields Group Ltd
JSE:GML
|
$58.65 Million |
|
AmFIRST Real Estate Investment Trust
KLSE:5120
|
$58.59 Million |
|
MCE Holdings Bhd
KLSE:7004
|
$58.57 Million |
|
Kedoya Adyaraya Tbk PT
JK:RSGK
|
$58.56 Million |
|
Wp Energy Public Company Limited
BK:WP
|
$58.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Heron Therapeuti's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -33,651,000 to 14,333,000, a change of 47,984,000.
- Net loss of 20,195,000 reduced equity.
- New share issuances of 26,169,000 increased equity.
- Other comprehensive income decreased equity by 9,000.
- Other factors increased equity by 42,019,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.20 Million | -140.9% |
| Share Issuances | $26.17 Million | +182.58% |
| Other Comprehensive Income | $-9.00K | -0.06% |
| Other Changes | $42.02 Million | +293.16% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Heron Therapeuti's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.00x to 3.60x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1987-12-31 | $158.78 | $0.31 | x |
| 1988-12-31 | $117.03 | $0.31 | x |
| 1989-12-31 | $79.93 | $0.31 | x |
| 1990-12-31 | $51.92 | $0.31 | x |
| 1991-12-31 | $24.80 | $0.31 | x |
| 1992-12-31 | $124.44 | $0.31 | x |
| 1993-12-31 | $61.55 | $0.31 | x |
| 1994-12-31 | $58.84 | $0.31 | x |
| 1995-12-31 | $25.27 | $0.31 | x |
| 1996-12-31 | $21.79 | $0.31 | x |
| 1997-12-31 | $41.92 | $0.31 | x |
| 1998-12-31 | $56.92 | $0.31 | x |
| 1999-12-31 | $47.40 | $0.31 | x |
| 2000-12-31 | $83.82 | $0.31 | x |
| 2001-12-31 | $75.65 | $0.31 | x |
| 2002-12-31 | $60.60 | $0.31 | x |
| 2003-12-31 | $43.84 | $0.31 | x |
| 2004-12-31 | $49.43 | $0.31 | x |
| 2005-12-31 | $19.76 | $0.31 | x |
| 2006-12-31 | $151.71 | $0.31 | x |
| 2007-12-31 | $30.45 | $0.31 | x |
| 2008-12-31 | $4.93 | $0.31 | x |
| 2009-12-31 | $4.17 | $0.31 | x |
| 2010-12-31 | $0.66 | $0.31 | x |
| 2011-12-31 | $1.57 | $0.31 | x |
| 2012-12-31 | $4.24 | $0.31 | x |
| 2013-12-31 | $4.27 | $0.31 | x |
| 2014-12-31 | $2.37 | $0.31 | x |
| 2015-12-31 | $3.57 | $0.31 | x |
| 2016-12-31 | $-0.56 | $0.31 | x |
| 2017-12-31 | $2.43 | $0.31 | x |
| 2018-12-31 | $5.06 | $0.31 | x |
| 2019-12-31 | $4.94 | $0.31 | x |
| 2020-12-31 | $2.61 | $0.31 | x |
| 2021-12-31 | $0.79 | $0.31 | x |
| 2022-12-31 | $0.12 | $0.31 | x |
| 2023-12-31 | $-0.25 | $0.31 | x |
| 2024-12-31 | $-0.22 | $0.31 | x |
| 2025-12-31 | $0.09 | $0.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Heron Therapeuti utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -140.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13.04%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 17.85x
- Recent ROE (-140.90%) is below the historical average (-111.91%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1987 | -22.09% | -223.53% | 0.08x | 1.22x | $-5.52 Million |
| 1988 | -37.59% | -200.00% | 0.15x | 1.26x | $-6.33 Million |
| 1989 | -47.37% | -160.71% | 0.21x | 1.39x | $-5.45 Million |
| 1990 | -61.90% | -162.50% | 0.21x | 1.84x | $-4.53 Million |
| 1991 | -138.71% | -153.57% | 0.29x | 3.10x | $-4.61 Million |
| 1992 | -27.72% | -76.71% | 0.26x | 1.40x | $-7.62 Million |
| 1993 | -94.29% | -49.75% | 0.82x | 2.32x | $-10.95 Million |
| 1994 | -83.05% | -61.64% | 0.68x | 1.99x | $-10.98 Million |
| 1995 | -180.77% | -58.39% | 0.70x | 4.44x | $-9.92 Million |
| 1996 | -188.00% | -50.27% | 1.02x | 3.68x | $-9.90 Million |
| 1997 | -17.65% | -10.47% | 0.71x | 2.37x | $-2.82 Million |
| 1998 | -18.62% | -13.50% | 0.87x | 1.59x | $-4.15 Million |
| 1999 | -17.50% | -10.29% | 0.87x | 1.96x | $-3.30 Million |
| 2000 | 40.42% | 254.07% | 0.12x | 1.28x | $6.44 Million |
| 2001 | -13.11% | -57.31% | 0.19x | 1.23x | $-4.43 Million |
| 2002 | -24.44% | -64.97% | 0.33x | 1.15x | $-5.32 Million |
| 2003 | -38.74% | -90.00% | 0.37x | 1.17x | $-5.49 Million |
| 2004 | -65.15% | -170.63% | 0.32x | 1.20x | $-10.64 Million |
| 2005 | -132.36% | -152.29% | 0.60x | 1.45x | $-8.83 Million |
| 2006 | 43.67% | 97.68% | 0.31x | 1.43x | $4.06 Million |
| 2007 | -68.41% | -4893.93% | 0.01x | 1.25x | $-23.11 Million |
| 2008 | -304.36% | -6266.94% | 0.03x | 1.55x | $-23.88 Million |
| 2009 | -147.56% | -795.24% | 0.14x | 1.32x | $-10.71 Million |
| 2010 | -558.21% | -564.64% | 0.45x | 2.21x | $-7.48 Million |
| 2011 | -75.00% | -1828.79% | 0.03x | 1.23x | $-13.39 Million |
| 2012 | -45.06% | 0.00% | -0.01x | 1.08x | $-28.53 Million |
| 2013 | -80.18% | 0.00% | 0.00x | 1.10x | $-62.18 Million |
| 2014 | -121.10% | 0.00% | 0.00x | 1.22x | $-82.67 Million |
| 2015 | -82.63% | 0.00% | 0.00x | 1.17x | $-109.40 Million |
| 2016 | 0.00% | -13537.37% | 0.02x | 0.00x | $-171.02 Million |
| 2017 | -150.59% | -641.87% | 0.13x | 1.79x | $-210.60 Million |
| 2018 | -48.31% | -230.84% | 0.17x | 1.25x | $-215.86 Million |
| 2019 | -50.70% | -140.27% | 0.28x | 1.27x | $-245.13 Million |
| 2020 | -94.90% | -253.20% | 0.25x | 1.50x | $-248.08 Million |
| 2021 | -280.60% | -252.08% | 0.28x | 3.94x | $-225.42 Million |
| 2022 | -991.13% | -124.93% | 0.43x | 18.49x | $-135.87 Million |
| 2023 | 0.00% | -87.02% | 0.57x | 0.00x | $-107.16 Million |
| 2024 | 0.00% | -9.41% | 0.62x | 0.00x | $-10.21 Million |
| 2025 | -140.90% | -13.04% | 0.61x | 17.85x | $-21.63 Million |
Industry Comparison
This section compares Heron Therapeuti's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $86,936,133
- Average return on equity (ROE) among peers: -19.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Heron Therapeuti (HRTX) | $9.14 Million | -22.09% | 25.95x | $58.62 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $117.14 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $318.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $992.51 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.17 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $431.75 Million | -14.19% | 0.73x | $4.70 Billion |
About Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It … Read more